Archive
A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Targeting Metabolic Vulnerabilities: Valinomycin Augments the Potency of Bioenergetic Inhibitors in Combatting Drug-Resistant and Dormant Mycobacterium tuberculosis
Tuberculosis (TB) treatment is hampered by monotherapy limitations and phenotypic drug tolerance, citing the need for effective drug combinations. The mycobacterial ele...
<a href="https://www.fiercebiotech.com/biotech/contineums-jj-partnered-ms-drug-fails-improve-vision-phase-2" hreflang="en">Contineum's J&J-partnered MS drug fails to improve vision in phase 2</a>
Contineum Therapeutics’ M1 receptor antagonist has failed to move the needle in a phase 2 vision test for patients with a common form of multiple sclerosis.
<a href="https://www.fiercebiotech.com/biotech/jjs-5b-alzheimers-hope-fades-anti-tau-antibody-posdinemab-flops-phase-2" hreflang="en">J&J's $5B Alzheimer's hope fades as anti-tau antibody posdinemab flops in phase 2</a>
Johnson & Johnson’s attempt to develop a $5 billion-a-year Alzheimer’s disease drug has been rocked by a phase 2 flop. A scheduled data review found the anti-tau antibo...
Regulatory actions for Nov. 25, 2025
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Celltrion, Hen...
UK-US drug pricing deal could come as early as this week, sources say
A major drug price deal between the US and UK government could be finalized as early as this week, two UK-based sources familiar with the matter told Endpoints News on...
Bayer’s asundexian hits phase III stroke goal in win for FXIa drugs
Detailed data will be forthcoming at a scientific congress, but Bayer AG’s positive top-line readout from its phase III study testing oral factor XIa (FXIa) inhibitor a...
Regulatory actions for Nov. 24, 2025
Regulatory snapshots, including global drug submissions and approvals, and other regulatory decisions and designations: Sangamo.
Eli Lilly becomes first drugmaker to hit $1 trillion in market value
The pharmaceutical company’s success developing medicines for obesity has swelled its worth to levels associated with tech titans like Apple and Google and dwarfed that...
Teva loses IRA drug pricing challenge in DC federal court
Teva’s challenge against Medicare negotiations fell flat in DC federal court, marking another loss for the pharma industry. US District Judge Sparkle Sooknanan said Thu...
Contineum's J&J-partnered drug fails Phase 2 multiple sclerosis trial
Contineum Therapeutics reported a Phase 2 failure in multiple sclerosis on Thursday afternoon, but most analysts don’t seem to view the miss as catastrophic. Contineum...
GSK, AnaptysBio enter legal battle over decade-old Jemperli licensing deal
GSK subsidiary Tesaro and AnaptysBio are at legal loggerheads over a licensing pact concerning the cancer drug Jemperli that dates back to 2014. On Thursday, GSK said T...
Eli Lilly becomes first drugmaker to hit $1 trillion in market value
The pharmaceutical company’s success developing medicines for obesity has swelled its worth to levels associated with tech titans like Apple and Google and dwarfed that...
FDA tests new program to speed drugmaker talks; Bezos-linked AI startup raises $106M
The FDA will now allow biotechs to ask agency staff for “quick clarifications” via email. Elsewhere, Novartis hiked guidance for two top drugs and a startup nearing “un...
Roche: Data for Breast Cancer Drug Candidate Giredestrant Support Potential Differentiated Status - Morningstar Canada
Roche: Data for Breast Cancer Drug Candidate Giredestrant Support Potential Differentiated Status Morningstar Canada
As Madrigal faces MASH rivals, keeping patients is as critical as finding new ones
Madrigal’s drug Rezdiffra has exceeded expectations, and the company plans to stay ahead of incoming competition with a highly targeted patient approach.
OLMA Stock Doubles After Roche Cancer Drug Trial Yields Positive Results - Stocktwits
OLMA Stock Doubles After Roche Cancer Drug Trial Yields Positive Results Stocktwits
New experimental drug could transform care for cancer patients - The Independent
New experimental drug could transform care for cancer patients The Independent
Is Now the Moment to Reassess Roche After Its Drug Pipeline Developments and 17% Stock Jump? - simplywall.st
Is Now the Moment to Reassess Roche After Its Drug Pipeline Developments and 17% Stock Jump? simplywall.st
Directory ribbon
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page Thermo Fisher Core Tools & Instruments
Track Danaher Core Tools & Instruments
Track Agilent Core Tools & Instruments
Track Merck KGaA Core Tools & Instruments
Track Illumina Core Tools & Instruments
Track Waters Core Tools & Instruments
Track Bruker Core Tools & Instruments
Track Sartorius Core Tools & Instruments
Track Mettler Toledo Core Tools & Instruments
Track PerkinElmer (Revvity) Core Tools & Instruments
Track Bio-Rad Core Tools & Instruments
Track Carl Zeiss Core Tools & Instruments
Track Leica Microsystems Core Tools & Instruments
Track Nikon Core Tools & Instruments
Track Eppendorf Core Tools & Instruments
Track Corning Core Tools & Instruments
Track BD (Becton Dickinson) Core Tools & Instruments
Track Beckman Coulter Core Tools & Instruments
Track Qiagen Core Tools & Instruments
Track Abcam Core Tools & Instruments
Track MGI Tech (华大智造) Core Tools & Instruments
Track Haier Biomedical Core Tools & Instruments